Amgen Inc. acquired ChemoCentryx, Inc. to expand its product portfolio that includes TAVNEOS, an orally given selective complement 5a receptor inhibitor. Furthermore, TAVNEOS was approved by the United States Food and Drug Administration (FDA) in 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis and is being explored in new inflammatory disorders, including hidradenitis suppurativa (HS), a severe and deforming chronic dermatological condition.
Ascentage Pharma Group International teamed up with Pfizer Inc. to investigate the combination of Ascentage Pharma's lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, and Pfizer's IBRANCE® (palbociclib), a CDK4/6 inhibitor, to assess the safety, tolerability, and anticancer efficacy of lisaftoclax in combination with palbociclib.in patients with metastatic breast cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5302
Published Date: Oct 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of Diffuse B-cell Lymphoma and the growing government initiatives are the major factors driving the growth of the market.
The market size of BCL-2 (B-cell lymphoma 2) Inhibitors is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024-2036.
The major players in the market are Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, Seagen Inc., Servier, AbbVie Inc., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG.
The combination therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.